Clinuvel Pharmaceuticals Ltd (CUV) - Total Assets
Based on the latest financial reports, Clinuvel Pharmaceuticals Ltd (CUV) holds total assets worth AU$269.70 Million AUD (≈ $190.83 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See CUV total equity for net asset value and shareholders' equity analysis.
Clinuvel Pharmaceuticals Ltd - Total Assets Trend (2000–2025)
This chart illustrates how Clinuvel Pharmaceuticals Ltd's total assets have evolved over time, based on quarterly financial data.
Clinuvel Pharmaceuticals Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Clinuvel Pharmaceuticals Ltd's total assets of AU$269.70 Million consist of 96.8% current assets and 3.2% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 82.5% |
| Accounts Receivable | AU$27.46 Million | 10.1% |
| Inventory | AU$8.82 Million | 3.3% |
| Property, Plant & Equipment | AU$7.13 Million | 2.6% |
| Intangible Assets | AU$185.03K | 0.1% |
| Goodwill | AU$185.03K | 0.1% |
Asset Composition Trend (2000–2025)
This chart illustrates how Clinuvel Pharmaceuticals Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CUV stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Clinuvel Pharmaceuticals Ltd's current assets represent 96.8% of total assets in 2025, an increase from 51.8% in 2000.
- Cash Position: Cash and equivalents constituted 82.5% of total assets in 2025, up from 51.3% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 47.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 10.1% of total assets.
Clinuvel Pharmaceuticals Ltd Competitors by Total Assets
Key competitors of Clinuvel Pharmaceuticals Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Ascendis Pharma AS
F:A71
|
Germany | €1.30 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.69 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098
|
China | CN¥1.56 Billion |
Clinuvel Pharmaceuticals Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.64 | 17.37 | 9.35 |
| Quick Ratio | 14.17 | 16.65 | 9.20 |
| Cash Ratio | 2.02 | 1.28 | 8.49 |
| Working Capital | AU$243.53 Million | AU$214.46 Million | AU$71.70 Million |
Clinuvel Pharmaceuticals Ltd - Advanced Valuation Insights
This section examines the relationship between Clinuvel Pharmaceuticals Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.82 |
| Latest Market Cap to Assets Ratio | 1.25 |
| Asset Growth Rate (YoY) | 17.6% |
| Total Assets | AU$271.75 Million |
| Market Capitalization | $339.22 Million USD |
Valuation Analysis
Above Book Valuation: The market values Clinuvel Pharmaceuticals Ltd's assets above their book value (1.25x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Clinuvel Pharmaceuticals Ltd's assets grew by 17.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Clinuvel Pharmaceuticals Ltd (2000–2025)
The table below shows the annual total assets of Clinuvel Pharmaceuticals Ltd from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$271.75 Million ≈ $192.28 Million |
+17.58% |
| 2024-06-30 | AU$231.12 Million ≈ $163.53 Million |
+18.81% |
| 2023-06-30 | AU$194.52 Million ≈ $137.64 Million |
+34.33% |
| 2022-06-30 | AU$144.81 Million ≈ $102.47 Million |
+33.39% |
| 2021-06-30 | AU$108.57 Million ≈ $76.82 Million |
+33.14% |
| 2020-06-30 | AU$81.54 Million ≈ $57.70 Million |
+30.79% |
| 2019-06-30 | AU$62.35 Million ≈ $44.11 Million |
+45.31% |
| 2018-06-30 | AU$42.90 Million ≈ $30.36 Million |
+49.98% |
| 2017-06-30 | AU$28.61 Million ≈ $20.24 Million |
+42.05% |
| 2016-06-30 | AU$20.14 Million ≈ $14.25 Million |
+47.60% |
| 2015-06-30 | AU$13.64 Million ≈ $9.65 Million |
-20.46% |
| 2014-06-30 | AU$17.15 Million ≈ $12.14 Million |
+8.47% |
| 2013-06-30 | AU$15.81 Million ≈ $11.19 Million |
-1.13% |
| 2012-06-30 | AU$16.00 Million ≈ $11.32 Million |
-20.68% |
| 2011-06-30 | AU$20.17 Million ≈ $14.27 Million |
-31.66% |
| 2010-06-30 | AU$29.51 Million ≈ $20.88 Million |
-29.09% |
| 2009-06-30 | AU$41.61 Million ≈ $29.44 Million |
-24.30% |
| 2008-06-30 | AU$54.97 Million ≈ $38.90 Million |
-18.95% |
| 2007-06-30 | AU$67.82 Million ≈ $47.99 Million |
+297.31% |
| 2006-06-30 | AU$17.07 Million ≈ $12.08 Million |
+69.76% |
| 2005-06-30 | AU$10.06 Million ≈ $7.12 Million |
-1.87% |
| 2004-06-30 | AU$10.25 Million ≈ $7.25 Million |
+27.04% |
| 2003-06-30 | AU$8.07 Million ≈ $5.71 Million |
-23.33% |
| 2002-06-30 | AU$10.52 Million ≈ $7.44 Million |
-23.59% |
| 2001-06-30 | AU$13.77 Million ≈ $9.74 Million |
-10.83% |
| 2000-06-30 | AU$15.44 Million ≈ $10.93 Million |
-- |
About Clinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with e… Read more